Pharmafile Logo

OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy

January 29, 2020 |  

Written by Gavin Jones, OPEN Health

The FDA has published their industry guidance on the topic of long term follow up (LTFU) post gene therapy. Please see a link to the full guidance below. In summary, they are stipulating that a good proportion of these therapies will require LTFU of up to fifteen years.

This presents significant challenge to manufacturers given that patients will, in that stretch of time, have multiple changes to their care settings and life circumstances. In addition to this, and if these therapies live up to their promise, treated ‘patients’ will potentially become chronically well and keen to disengage from their previous disease state and their healthcare professionals.

This is a significant challenge but achievable! We have already shared our experienced thinking on this topic and a link to our article is provided below. Our recommendations focus on putting the patient at the centre of a solution and wrapping a, digitally enabled, registry solution around thoughtful patient and healthcare professional engagement.

Please read our full thinking below:

http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=5cf08b2f-f3d9-435a-8255-ef07542eb9a3&pnum=31

https://www.fda.gov/media/113768/download

Pink divider

Get in touch

If you would like to discuss further please contact our director of rare disease: gavinjones@openhealthgroup.com

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

Spotlight interview: 15 minutes on medical and scientific writing

Rob Pilbrow, Global Managing Director, Medical Writing, OPEN Health takes 15 minutes to answer some key questions on scientific writing

Spotlight interview: 15 minutes on healthcare advertising

Marie Little, Managing Director, OPEN Health Patient & Brand Communications takes 15 minutes to answer some key questions on healthcare advertising

Alexander Devine Website has gone live!

As part of the OPEN Health CSR programme one of the charities we support is Alexander Devine. They are a local Children's Hospice based in Maidenhead who provide a truly...

Spotlight interview: 15 minutes on patient-centricity in pharma

Sumira Riaz, Health Psychologist at OPEN Health Patient & Brand Communications, takes 15 minutes to answer some key questions on patient-centricity in pharma.

Spotlight interview: 15 minutes on patient engagement in pharma

Richard Jones, Managing Director Patient Engagement, OPEN Health Patient and Brand Communications, takes 15 minutes to answer some key questions on patient engagement in pharma

Rob Pilbrow joins OPEN Health as Global Managing Director, Medical Writing

OPEN Health Group have appointed Rob Pilbrow into the newly formed role of Global Managing Director, Medical Writing.

Spotlight interview: 15 minutes on the procurement function in pharma

Carwyn Jones, Senior Partner at OPEN Health, takes 15 minutes to answer some key questions on the procurement function in pharma.

Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era

The third plenary session at ISPOR in New Orleans focused on affordability in the face of new and expensive therapies and asked the question “is affordability driving a need to...

OPEN Health Medical Communications announces Group MD promotions and welcomes new Creative Director

OPEN Health Medical Communications has announced the promotion of two members of its senior leadership team. Jen van Zwieten and Margot Hannah become Group Managing Directors, with responsibility to oversee...

OPEN Health Graduates and the XP Support Group

During our graduate induction period in September 2018, we were asked to find a charity that could benefit from the expertise of the OPEN Health practices. We made the decision...